Sensex falls as heavyweights tumble

REUTERS - Indian shares fell on Thursday, dragged lower by heavyweights such as Reliance Industries as well as financial and technology stocks, signalling low risk appetite among investors ahead of some key company results.

Indexes in Asia's second-largest economy tracked losses in regional shares after weak China trade data rekindled global growth worries.

China's September exports fell 10 percent from a year earlier, far more than markets had expected, while imports unexpectedly shrank 1.9 percent.

Back home, caution prevailed ahead of quarterly results of software exporter Tata Consultancy Services , which fell 2.1 percent. TCS is expected to report results on Thursday after the market closes, ahead of Infosys' results, which is due on Friday.

"China has been a concern for a very long time and today's data indicates that exports are not up to the mark. So markets are seeing a correction. But going ahead, focus remains on quarterly results," said AK Prabhakar, head of research at IDBI Capital.

The benchmark BSE Sensex was 0.85 percent lower at 27,848.71 as of 0512 GMT, while the NSE Nifty was down 0.92 percent at 8,628.32. Both indexes hit their lowest in two weeks.

Indian financial markets were shut on Tuesday and Wednesday for public holidays.

Index heavyweights such as Reliance Industries was down 1.5 percent while Housing Development Finance Corp declined 2.5 percent.

Mining stocks such as Hindalco Industries and Vedanta Ltd also fell more than 1.5 percent.

The Nifty Metal index was down nearly 1 percent, reflecting weakness in global metal prices after exports at the world's biggest metals consumer China fell more than expected in September.

Blue Dart Express fell 2.7 percent after the package delivery company reported a near 21 percent drop in September-quarter profit, missing analysts' estimates.

Among the gainers, IndusInd Bank rose as much as 2 percent after the lender on Wednesday posted a near-26 percent rise in September-quarter profit.

Cipla rose 1.3 percent after the drugmaker said on Wednesday that the U.S. Food and Drug Administration cleared its manufacturing facility at Indore.

(Reporting by Aastha Agnihotri in Bengaluru; Editing by Amrutha Gayathri)